Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye fluid analysis may unlock clues for untreated form of macular degeneration

NCT ID NCT03418220

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study examined inflammation markers in the fluid from the eyes of 82 people with different stages of age-related macular degeneration (AMD) and a control group without AMD. Researchers collected samples during cataract surgery and tested for 27 inflammation-related molecules. The goal was to identify specific patterns that could help understand the dry (atrophic) form of AMD, for which no treatment currently exists, and potentially guide future therapies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If specific inflammation markers are found in atrophic AMD, this could point toward new targeted treatments for a form of the disease that currently has no therapy.
What could go wrong
This is an observational study, not a treatment trial. It is small (82 participants) and only looks at markers in eye fluid, so any link to future therapies is uncertain and far off.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

82 people

The number who actually took part.

Started

Nov 2017

Finished

Sep 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • GENERAL CRITERIA * Man or woman with age over 60 years, * Informed, written and signed consent by the patient and the investigator (no later than the day of inclusion) and before any investigation required by the research, * Patient affiliated with social security, * Patient willing and able to return to all clinical visits to the study and complete all related procedures. • SPECIFIC CRITERIA * Patient who need a cataract surgery, * Patient presenting in both eyes: the same type of AMD defined according to the international AREDS study modified (Ferris et al., 2013) no other ophthalmological pathology (control group). Exclusion Criteria: * • GENERAL CRITERIA * Major patient under tutorship or curatorship or unable to express consent, * Person deprived of liberty, * Patient participating in an ongoing clinical trial during the inclusion visit, • SPECIFIC CRITERIA * Patient with chronic ophthalmic pathologies other than cataract and AMD defined in the modified international AREDS study included in the eye (Ferris et al., 2013), * Patient who participated in a clinical trial of an experimental drug for atrophic AMD, * Patient taking systemically drugs with immunomodulatory action: immunosuppressants, immunomodulators, chemotherapy or corticosteroids, * Patient with systemic diseases modifying his immune status, * Patient with a history of diabetes, * Patient who received an anti-inflammatory eye treatment in both eyes in the 6 months preceding the surgery, * Patient having dynamic phototherapy on the included eye.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrophic age-related macular degeneration are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration Atrophy dry age related macular degeneration Inflammation macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Macular degeneration, age related

Contacts and locations

Locations

  • Hôpital de la Croix-Rousse

    Lyon, 69004, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.